Literature DB >> 25959078

Reconstruction algorithm for nasal basal cell carcinoma with skin involvement only: analysis of 221 cases repaired by minor surgery.

Y J Kim1, H H Cho2, S O Kim3, J B Lee1, S C Lee1.   

Abstract

BACKGROUND: Basal cell carcinoma (BCC) often occurs on the nose. Reconstruction of the nose should yield excellent aesthetic and functional outcomes. AIM: We propose a technical algorithm for the reconstruction of surgical defects, based on our analysis of 221 cases of nasal BCC with skin involvement only, which could be repaired by minor surgery.
METHODS: The aesthetic and functional outcomes for various reconstruction techniques were analysed according to defect location and size. A reconstruction algorithm was proposed with the aim of obtaining the best surgical results.
RESULTS: Defect location and size were key considerations. Primary closure was the first option for small defects (< 10 mm), with scores of 3.4 for objective aesthetic outcome (OAO), 3.2 for subjective aesthetic outcome (SAO) and 3.3 for subjective functional outcome (SFO). The first option for medium defects (1-20 mm) was the island pedicle flap, with scores of 3.5 for OAO, 3.2 for SAO and 3.7 for SFO. The first option for large defects (> 20 mm) was the transposition flap for the upper nose (scores of 2.0 for OAO and SAO and 3.0 for SFO) and the interpolation flap for the lower nose (2.8 for OAO and 2.9 for SAO and SFO).
CONCLUSIONS: We have proposed an algorithm to select the optimal technique for repairing nasal BCC surgical defects according to their size and location.
© 2015 British Association of Dermatologists.

Entities:  

Mesh:

Year:  2015        PMID: 25959078     DOI: 10.1111/ced.12676

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  1 in total

1.  Tumor Control and Quality of Life in Skin Cancer Patients With Extensive Multilayered Nasal Defects.

Authors:  Michaela Plath; Hannah M Thielen; Ingo Baumann; Karim Zaoui; Philippe A Federspil
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-08-03       Impact factor: 3.372

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.